Asymmetrex® Introduces Rapid Online Stem Cell Counting to First Cell Culture Core Facility at UMassAmherst's Applied Life Sciences Laboratory

featured image

This month, stem cell biotechnology company Asymmetrex® launched a campaign to introduce its new online calculator for rapid counting of therapeutic tissue stem cells to cell culture core facilities at major research universities. today, September 20Asymmetrex® President and CEO, James L. Shirley MDPhD UMassAmherst introduces campaigns directly to users of the Cell Culture Core Facility.

Boston, September 20, 2022 /PRNewswire-PRWeb/ — Outside the world of experimental science, one of the most important groups that contributed to the excellence of US biomedical research is largely unknown to most. This modest group consists of the Director of the Research Core Facility and the technical staff.

Research core facilities provide scientific and technical expertise using high-end equipment and technology that are typically too expensive and complex for individual research institutions to independently obtain and effectively utilize. facilitate and accelerate the research pursued by users. Core facility personnel also play an important role in fulfilling the institution’s educational mission of nurturing the next generation of outstanding biomedical researchers.

As cell culture core facilities at major research institutions play a central role in stem cell medicine research, Asymmetrex® is the first focus of introducing a new online calculator for rapid counting of therapeutic tissue stem cells. We have selected these facilities. The Cell Culture Core Facility’s standard research services, including human tissue cell expansion and enumeration, are directly integrated into Asymmetrex’s online portal for rapid stem cell enumeration.

Prior to the availability of Asymmetrex technology, there was no routine and convenient method for counting tissue stem cells. Stem cells are always found in admixture with other tissue cells, making them difficult to identify and count. The need for methods to quantify tissue stem cells has significantly hampered both stem cell research and stem cell medicine for more than half a century. Asymetrex counting technology is the first solution to this long-standing need for a means of monitoring tissue stem cells in experiments and determining dosage for more effective stem cell therapy.

today, September 20Asymetrex President and CEO, James L. ShirleyMD, Ph.D. introduces new counting techniques to users of the Cell Culture Core Facility at the Institute for Applied Life Sciences. University of Massachusetts AmherstHis presentation will be the first seminar of the year in the IALS Core Facility Seminar Series.

The UMassAmherst core facility was the ideal choice for Asymmetrex to first introduce the capabilities and benefits of its new online stem cell calculator. Many of the validation studies for new stem cell counting techniques were conducted by the UMassAmherst Cell Culture Core Facility. Michael P. DailyDirector Daley is one of the first core facility directors in the country to provide users with access to rapid enumeration of two types of tissue stem cells widely used in stem cell research: cord blood stem cells and mesenchymal stem cells. I’m a person. In the future, through his core facility, UMassAmherst faculty, students, trainees, and research staff will be able to add to online calculators to count many other types of important tissue stem cells used in research. You will also be able to obtain access.

Asymmetrex CEO Sherley said he is looking forward to this first in-person introduction to the core facility. The company is also planning a webinar series to enable core facility directors anywhere in the United States to learn about what UMassAmherst has already launched. “After meeting UMassAmherst, a week later he is scheduled for the first national webinar of the core facility introduction series on September 27th!”

About Asymetrex®

Asymmetrex®, LLC is Massachusetts A life sciences company focused on developing technologies that advance stem cell medicine. The company’s US and UK patent portfolio contains two major technical problems that have hindered the more effective use of human adult tissue stem cells for regenerative medicine and drug development: stem cell-specific quantification and stem cell includes biotechnology that solves proliferation). Asymmetrex markets Kinetic Stem Cell (KSC) counting, the first technology for determining dosage and quality of tissue stem cell formulations for use in stem cell transplant medicine and preclinical drug evaluation. Asymmetrex® is a member company of the Advanced Regenerative Manufacturing Institute|BioFabUSA (ARMI) and the Massachusetts Biotechnology Council (MassBio). The company’s development of an online calculator for rapid stem cell counting is funded by research and development grants from ARMI|BioFabUSA and the National Heart, Lung, and Blood Institute.

media contact

James L. ShirleyMD, Ph.D., Asymmetrex® LLC, 16179906819,

twitterLinkedIn, Facebook

Source Asymmetrex® LLC